Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX/TEZ/IVA in cystic fibrosis subjects aged 12 to less than 24 months
NL-OMON60595Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of elexacaftor, tezacaftor and ivacaftor, sponsored by Vertex Pharmaceuticals. Started Jul 2024; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
Beyond the preview
Go deeper on NL-OMON60595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60595.